- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07465653
En sikkerhets- og tolerabilitetsstudie av HJB647 for hjerteinsufficienspasienter med redusert ejeksjonsfraksjon
Et multicentret, randomisert, deltaker- og undersøker-blindet, placebo-kontrollert kryssstudie for å undersøke sikkerheten, toleransen og farmakokinetikken til HJB647 hos deltakere med kronisk stabil hjertesvikt med redusert ejeksjonsfraksjon
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is a multi-center, randomized, participant- and investigator- blinded, placebo- controlled crossover study to investigate the safety, tolerability, and pharmacokinetics of HJB647 in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
The study will consist of approximately 12 participants randomly assigned in a 1:1:1 ratio to one of three 3-day treatment sequences comprised of two doses of HJB647 and placebo. Dosing of the HJB647 and placebo is planned for 3 consecutive days. Participants will be domiciled during study drug administration period for close monitoring with a follow-up in-clinic visit on Day 7. A safety call will be performed on Day 33.
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Novartis Pharmaceuticals
- Telefonnummer: 1-888-669-6682
- E-post: novartis.email@novartis.com
Studer Kontakt Backup
- Navn: Novartis Pharmaceuticals
- Telefonnummer: +41613241111
Studiesteder
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Rekruttering
- Novartis Investigative Site
-
Sherbrooke, Quebec, Canada, J1E 0N8
- Rekruttering
- Novartis Investigative Site
-
-
-
-
Florida
-
Bradenton, Florida, Forente stater, 34208
- Rekruttering
- Synergy Healthcare
-
Hovedetterforsker:
- Patrick Weston
-
Ta kontakt med:
- Shannon Stickels
- E-post: sstickels@synergyhealthcorp.com
-
Inverness, Florida, Forente stater, 34452
- Rekruttering
- Nature Coast Clinical Research LLC
-
Hovedetterforsker:
- Rafik Abadier
-
Ta kontakt med:
- Jill Barnett
- Telefonnummer: +1 352 341 2100
- E-post: jbarnett@flourishresearch.com
-
Jacksonville, Florida, Forente stater, 32216
- Rekruttering
- Jacksonville Center for Clinical
-
Hovedetterforsker:
- Michael J Koren
-
Ta kontakt med:
- Sara Villotti
- Telefonnummer: +1 904 730 0101
- E-post: svillotti@flourishresearch.com
-
Miami Lakes, Florida, Forente stater, 33014
- Rekruttering
- Inpatient Research Clinical LLC
-
Hovedetterforsker:
- Alexis Gutierrez
-
Ta kontakt med:
- Lazaro Rivero
- Telefonnummer: +1 786 502 4303
- E-post: lrivero@inpatientresearch.com
-
Winter Park, Florida, Forente stater, 32789
- Rekruttering
- Flourish Research
-
Hovedetterforsker:
- Monica Aggarwal
-
Ta kontakt med:
- Sara Contreras
- E-post: scontreras@flourishresearch.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Participants eligible for inclusion in this study must meet all of the following criteria:
- Men and women aged 18 years or older
- Stable NYHA functional class II-III
- LVEF <50%
- NT-proBNP ≥600 pg/ml if in sinus rhythm or ≥900 pg/ml if in atrial fibrillation at screening
- On stable standard of care therapy with sacubitril/valsartan for at least 4 weeks before screening.
Exclusion Criteria:
Participants will be deemed ineligible for inclusion if they meet any of the following exclusion criteria:
- Acute decompensated heart failure within 3 months prior to screening
- SBP <105 mmHg at screening or baseline.
- Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, PCI, or carotid angioplasty within the 6 months prior to screening
- Hemodynamically significant mitral and/or aortic valve disease, or any prior valve replacement, except mitral regurgitation secondary to LV dilation at screening
- eGFR <30 ml/min/1.73m2 at screening, as measured by the CKD-EPI formula
- BMI >40 kg/m2
- Strong CYP3A4 inhibitors or inducers, sGC activators (vericiguat), PDE5 inhibitors, and nitroglycerin products
- Women of childbearing potential
Further eligibility criteria might apply in alignment with the trial protocol.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
Taken by mouth as capsules |
Placebo control in capsule form |
|
Eksperimentell: HJB647 low dose
Taken by mouth as capsule |
Study drug low dose in capsule form |
|
Eksperimentell: HJB647 high dose
Taken by mouth as capsule |
Study drug high dose in capsule form |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with Adverse Events (AEs)
Tidsramme: Up to 33 days
|
Number of participants with AEs as a measure of safety and tolerability |
Up to 33 days
|
|
Number of participants with clinically significant changes in vital signs
Tidsramme: Up to 33 days
|
Number of participants with clinically significant changes in Systolic Blood Pressure, Diastolic Blood Pressure, Heart Rate, Electrocardiogram and hyposensitive events as a measure of adverse events |
Up to 33 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetics: Maximum concentration (Cmax)
Tidsramme: Up to 7 days
|
Maximum concentration (Cmax) of the trial drug in participants' blood |
Up to 7 days
|
|
Pharmacokinetics: Time to reach maximum plasma concentration (Tmax)
Tidsramme: Up to 7 days
|
Time to require the trial drug to reach its maximum concentration in participants blood |
Up to 7 days
|
|
Pharmacokinetics: Area Under the Concentration-Time Curve from dosing form to the last measurable concentration (AUClast)
Tidsramme: Up to 7 days
|
Area under the curve from time zero to the last measurable concentration sampling time |
Up to 7 days
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CHJB647A12103
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .